This analysis also revealed that PEM efficacy was negatively associated with the vital biomarkers for CRC patient outcomes, such as the levels of carcinoembryonic antigen (CEA) and carbohydrate antigen199 (CA199) (Figure 7G–J). Here, CEACAM5 is linked to colorectal carcinoma.